Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229790 | 0.89 | OPRM1 (0.35) | OPRM1KCNH2SIGMAR1ALDH1A1MAPT | |
| SCHEMBL8763124 | 0.85 | ALDH1A1 (0.33) | ALDH1A1MAPTDRD3 | |
| SCHEMBL15775212 | 0.82 | BRD4 (0.36) | ALDH1A1MAPT | |
| SCHEMBL30661775 | 0.79 | EPHX1 (0.41) | ALDH1A1 | |
| SCHEMBL1274847 | 0.78 | MAPT (0.45) | ALDH1A1MAPTSMN1; SMN2GAANPSR1 | |
| SCHEMBL19598020 | 0.74 | TACR1 (0.45) | OPRM1KCNH2SIGMAR1 | |
| SCHEMBL27098380 | 0.72 | — | — | |
| SCHEMBL8164049 | 0.72 | — | — | |
| SCHEMBL16189945 | 0.72 | — | — | |
| SCHEMBL12528307 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022188819-A1 | SOS1 PROTEOLYSIS MODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-09-15 | — | — | WO | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| US-9969710-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | OPRM1 3583/4885KCNH2 4566/4885SIGMAR1 4135/4885 |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | OPRM1 4202/4885KCNH2 3779/4885SIGMAR1 2212/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | OPRM1 4202/4885KCNH2 3779/4885SIGMAR1 2212/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | OPRM1 3583/4885KCNH2 4566/4885SIGMAR1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.